Here Nancy McGee JD DrPH, SVP Health Policy and Public Payers at Lumanity, shares her insights on some of the potential outcomes of the Program and on the importance of scenario planning for pharmaceutical companies of all sizes during this period of uncertainty.

Although there are currently many unanswered questions about the impact of the Program, there are still a number of steps manufacturers can be taking now to prepare.

Read the full article

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.